Can PharmAla’s three year stability program de risk MDMA distribution challenges?
PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.
Novo Nordisk’s CagriSema misses non-inferiority against tirzepatide: Why a 23% weight loss still reshapes the obesity pipeline
Novo Nordisk A/S disclosed headline Phase 3 data from the REDEFINE 4 trial showing that CagriSema, its fixed-dose combination of cagrilintide and semaglutide, achieved 23 percent weight loss over 84 weeks in people with obesity but failed to meet the primary endpoint of non-inferiority versus tirzepatide. The open-label head-to-head study compared once-weekly CagriSema 2.4 mg/2.4 […]
How Sōlaria Biō is positioning Bōndia for credibility in a crowded bone health market
Sōlaria Biō validates gut delivery and control of Bōndia microbes. Read what the study really means for bone health and medical foods.
Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer
Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.
Are lymphatic system supplements moving from folklore to functional claims? A look at PureHealth Research
Explore what PureHealth Research’s lymphatic supplement launch reveals about evidence gaps, regulation, and risks in botanical congestion relief.
Why AltaPointe’s ketamine-assisted protocol could reshape opioid withdrawal management
Find out how a low-dose ketamine protocol may help fentanyl users start buprenorphine faster and with less withdrawal discomfort.
FDA approval of milsaperidone puts Vanda Pharmaceuticals into crowded bipolar I disorder and schizophrenia markets
FDA approves milsaperidone for bipolar I disorder and schizophrenia. Explore what this means for psychiatry, competition, and Vanda Pharmaceuticals’ strategy.
Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
Why YolTech Therapeutics’ YOLT-202 data matters for the future of gene editing in Alpha-1 Antitrypsin Deficiency
Early YOLT-202 data from YolTech Therapeutics suggests gene editing could redefine Alpha-1 Antitrypsin Deficiency treatment. Read the analysis.
What Enveric Biosciences’ EB-003 data reveal about separating benefit from hallucinations
Enveric Biosciences reports new EB-003 signaling data. Find out what this means for non-hallucinogenic antidepressant development and regulatory risk.